Stichting European Myeloma Network

This phase 3 study tested whether adding daratumumab to the standard two-drug regimen (pomalidomide and dexamethasone) could help people with relapsed or refractory multiple myeloma live longer without their cancer worsening. The trial enrolled 304 adults who had already tried at…

This study tested a drug called belantamab mafodotin in 35 people with AL amyloidosis, a rare disease where abnormal proteins build up in organs. All participants had already received at least one prior treatment. The goal was to see how many patients achieved a significant reduc…